20 articles
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
Scientists reveal CFTR protein prevents cardiomyocyte senescence by reducing mitochondrial oxidative stress via a newly discovered deubiquitination pathway.
Dive deep into the molecular mechanisms of vascular aging and explore cutting-edge interventions — from senolytic therapies and nitric oxide restoration to exercise-induced remodeling and emerging pharmacological approaches — that are redefining what's possible in cardiovascular longevity.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
Senescent macrophages and cell death pathways fuel atherosclerosis — and new drug targets may finally interrupt the cycle.
TREM-1 inhibitor LR12 reduced harmful plaque formation in stents by nearly 50% without affecting healing in rabbit studies.
New research shows citrate supplementation restores blood vessel function and extends lifespan by improving mitochondrial health.
A new analysis shows olezarsen reduces apoC-III by up to 75% across chylomicrons, HDL, LDL/VLDL, and Lp(a) in familial chylomicronemia syndrome.
New research reveals how berberine protects the heart in diabetes by activating cellular cleanup of harmful fat accumulation.
Ongericimab slashed LDL cholesterol by over 66% vs placebo in a phase 3 trial, offering a promising option for patients who can't tolerate statins.
SHR-1918 antibody dramatically reduced LDL cholesterol in patients with severe genetic hypercholesterolemia through novel pathway.
Meta-analysis shows ongericimab dramatically reduces LDL cholesterol and other heart disease risk factors with minimal side effects.
Breakthrough oral medications show dramatic cholesterol reduction with minimal side effects, offering new hope for heart health.
Enlicitide, the first oral PCSK9 inhibitor, dramatically reduced LDL cholesterol levels in cardiovascular disease patients over 52 weeks.
A new nanoparticle system delivers rapamycin and a DNA scavenger directly to arterial plaques, cutting inflammation and improving plaque stability in mice.
Meta-analysis shows recaticimab dramatically reduces LDL cholesterol and other cardiovascular risk markers with manageable side effects.
